{"disease":{"id":"extensive-stage-small-cell-lung-cancer","name":"extensive stage small cell lung cancer"},"drugs":{"marketed":[{"drug_id":"tarlatamab","indication_name":"extensive stage small cell lung cancer (ES-SCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imdelltra (Amg757)","generic_name":"TARLATAMAB","company_name":"Amgen Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer."},{"drug_id":"tarlatamab","indication_name":"extensive stage small cell lung cancer (ES-SCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imdelltra (Amg757)","generic_name":"TARLATAMAB","company_name":"Amgen Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06530797","title":"A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT07472517","title":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":670,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06748495","title":"Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT04063163","title":"A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":true},{"nct_id":"NCT06211036","title":"Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":563,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06646276","title":"A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":530,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04878016","title":"A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":498,"lead_sponsor_name":"Lee's Pharmaceutical Limited","has_results":false},{"nct_id":"NCT04213937","title":"Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":386,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07037758","title":"A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07005128","title":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":330,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04254471","title":"This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":313,"lead_sponsor_name":"Haihe Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT07390565","title":"YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":308,"lead_sponsor_name":"LI FENG","has_results":false},{"nct_id":"NCT05874401","title":"Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":302,"lead_sponsor_name":"Pharmacosmos A/S","has_results":false},{"nct_id":"NCT04663438","title":"Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04894591","title":"To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)","phase":"","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT06598306","title":"Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT00791154","title":"QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":213,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT07489339","title":"MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Shanxi Province Cancer Hospital","has_results":false},{"nct_id":"NCT05468489","title":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT05280470","title":"Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":187,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03516084","title":"A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":185,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT05361395","title":"First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06719336","title":"Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":182,"lead_sponsor_name":"Anhui Shi, MD","has_results":false},{"nct_id":"NCT05991180","title":"Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT03911219","title":"Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT04774380","title":"Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06479473","title":"Radiotherapy to All Residual Lesions After Chemoimmunotherapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT06663098","title":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":142,"lead_sponsor_name":"Gruppo Oncologico Italiano di Ricerca Clinica","has_results":false},{"nct_id":"NCT06362252","title":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":123,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT07107490","title":"A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT04702880","title":"A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07328490","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04902885","title":"Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Jiangsu Simcere Pharmaceutical Co., Ltd.","has_results":true},{"nct_id":"NCT06961201","title":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04985851","title":"To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT05903092","title":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":84,"lead_sponsor_name":"Hirva Mamdani","has_results":false},{"nct_id":"NCT06332950","title":"Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Baohui Han","has_results":false},{"nct_id":"NCT04790539","title":"a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":71,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT04404543","title":"A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":71,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT03841136","title":"Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05055947","title":"Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT06008353","title":"A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05055999","title":"Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT05484583","title":"Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":58,"lead_sponsor_name":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","has_results":false},{"nct_id":"NCT06838208","title":"Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Anhui Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT06478043","title":"A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT04101357","title":"Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"BioNTech SE","has_results":true},{"nct_id":"NCT07459634","title":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT06323265","title":"A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT06931145","title":"Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":50},"guidelines":[{"drug_id":"durvalumab","guideline_body":"FDA label","recommendation":"IMFINZI in combination with etoposide and either carboplatin or cisplatin as first-line treatment.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}